Sesen Bio (Sesen Bio) Debt-to-Asset : 0.00 (As of Dec. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Sesen Bio Debt-to-Asset?

Sesen Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.00 Mil. Sesen Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.00 Mil. Sesen Bio's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2022 was $189.17 Mil. Sesen Bio's debt to asset for the quarter that ended in Dec. 2022 was 0.00.

Sesen Bio Debt-to-Asset Historical Data

The historical data trend for Sesen Bio's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sesen Bio Debt-to-Asset Chart

Sesen Bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

Sesen Bio Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Sesen Bio's Debt-to-Asset

For the Biotechnology subindustry, Sesen Bio's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sesen Bio's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sesen Bio's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sesen Bio's Debt-to-Asset falls into.

Sesen Bio Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sesen Bio's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	189.174
	=	0.00

Sesen Bio's Debt-to-Asset for the quarter that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	189.174
	=	0.00

Sesen Bio (NAS:SESN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Sesen Bio Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Sesen Bio's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sesen Bio (Sesen Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sesen Bio Inc (NAS:SESN) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 First Street, Suite 1800, Cambridge, MA, USA, 02142

Website

https://www.sesenbio.com

Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.

Executives

Modernatx, Inc.	10 percent owner	200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Sanford S Zweifach	director	21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Steven Kelly	director, officer: President and CEO	C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Briggs Morrison	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Richard Steven Morris	officer: Chief Financial Officer	397 EAGLEVIEW BOULEVARD, EXTON PA 19341
Chidozie Ugwumba	director	158 FILMORE STREET, DENVER CO 80206
Bjorn Odlander	director	C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Michael Klichinsky	officer: Chief Scientific Officer	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Michael Torok	director	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Regina Hodits	director	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Elly Ryu	officer: Principal Accounting Officer	245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Glen C Macdonald	officer: Chief Technology Officer	245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Monica Forbes	officer: Chief Financial Officer	3344 NORTH TORREY PINES CT., SUITE 200, SAN DIEGO CA 92037
Thomas R Cannell	director, officer: President and CEO	C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Mark Sullivan	officer: General Counsel & Secretary	1000 BISHOPS GATE BOULEVARD, SUITE 300, MOUNT LAUREL NJ 08054